Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.
Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.
Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.
Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.
Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.
Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.
Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.
Panelists discuss how the ARANOTE trial exploring darolutamide in combination with androgen deprivation therapy shows potential benefits in managing advanced prostate cancer.
Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.
Panelists discuss how the SPLASH trial investigating 177Lu-PNT2002 demonstrates promising efficacy in treating advanced cancer through targeted radionuclide therapy.
Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.
